The YGVB epidemic caused measurable disruptions:
Economic modeling suggests that early vaccination combined with robust surveillance could avert up to $2.5 billion in direct healthcare costs annually. ygvb virus
Viral load correlates with disease severity, and the Ygvb‑tox gene product appears to trigger a cytokine cascade that contributes to tissue damage. The YGVB epidemic caused measurable disruptions:
A recombinant virus‑like particle (VLP) vaccine (YGVB‑VLP) entered Phase III trials in 2025. Early data show: Viral load correlates with disease severity, and the
The vaccine received Emergency Use Authorization (EUA) in several high‑risk regions in early 2026, and mass‑vaccination campaigns are underway, targeting schoolchildren and frontline workers.